Mean body weight reduction in the three highest dose groups (3.5-6 mg) reached about 3%, compared to about 1% weight gain in ...

ORKA-001: a novel half-life extended IL-23p19 monoclonal antibody Oruka plans to initiate a Phase 1 trial of ORKA-001 in the ...

There is also an oral GLP-1 RA peptide called MET-002 ... “We now have three medicines in the clinic with more to come, based ...

Continued execution across all programs, including positive results up to nine months from APG777 Phase 1 trial that continue to support ...

potential once-monthly injectable GLP-1 RA engineered with Metsera’s HALO™ lipidation platform. MET-097i showed a 7.5% reduction in body weight from baseline at day 36 and a 380-hour half-life.

A study of Gila monster venom helped start the revolution in weight-loss drugs. But scientists think that’s just the ...

AI should be viewed as a tool to enhance productivity and streamline operations, rather than as a replacement for human ...

Supplements promising similar results to Ozempic have taken over social media, but the TGA and health experts have concerns.

Good day and thank you for standing by. Welcome to the Absci Q3 2024 Business Update Conference Call. At this time, all ...

Throughout 2024, standalone mixed-reality headset buzz has largely been a tossup between the Meta Quest 3, a standalone ...

Company remains on track in late-stage, potentially registrational trials of nemvaleukin alfa, with data readouts expected in late Q1/early Q2 ...

A few months ago, we shared results from our non-human primate studies of this program demonstrating 2x to 3x extended half life as compared to first-generation ... We plan to initiate Phase 1 ...